Ferumoxytol

Ferumoxytol is an iron oxide-based contrast agent used in magnetic resonance imaging (MRI) and other medical imaging procedures, developed by AMAG Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) in 2009. It is also used to treat iron deficiency anemia in adult patients with chronic kidney disease (CKD), as recommended by the National Kidney Foundation and the American Society of Nephrology. Ferumoxytol has been compared to other iron supplements such as ferric gluconate and iron sucrose in terms of its efficacy and safety profile, as studied by researchers at Harvard University and published in the Journal of the American Society of Nephrology. The use of ferumoxytol has been supported by organizations such as the Kidney Disease: Improving Global Outcomes (KDIGO) and the European Renal Association.

● Introduction

Ferumoxytol is a semi-synthetic ultrasmall superparamagnetic iron oxide (USPIO) particle, composed of a iron oxide core and a carboxymethyl dextran coating, similar to other iron oxide nanoparticles developed by researchers at Massachusetts Institute of Technology (MIT) and Stanford University. It is administered intravenously and has a half-life of approximately 15 hours, allowing for prolonged imaging and diagnostic capabilities, as demonstrated in studies published in the Journal of Magnetic Resonance Imaging and the American Journal of Roentgenology. Ferumoxytol has been used in various medical imaging applications, including cardiovascular imaging and cancer imaging, at institutions such as Johns Hopkins University and University of California, Los Angeles (UCLA). The development of ferumoxytol has been influenced by the work of researchers at National Institutes of Health (NIH) and the European Organization for Research and Treatment of Cancer (EORTC).

● Chemistry

The chemical structure of ferumoxytol consists of a iron oxide core with a diameter of approximately 7 nanometers, surrounded by a carboxymethyl dextran coating, which provides stability and biocompatibility, similar to other polymer-coated nanoparticles developed by scientists at University of California, Berkeley and Carnegie Mellon University. The iron oxide core is composed of maghemite and magnetite, which are responsible for its superparamagnetic properties, as studied by researchers at University of Oxford and California Institute of Technology (Caltech). Ferumoxytol has a molecular weight of approximately 750 kDa and is highly soluble in water, making it suitable for intravenous administration, as demonstrated in studies published in the Journal of Pharmaceutical Sciences and the European Journal of Pharmaceutics and Biopharmaceutics. The chemical properties of ferumoxytol have been compared to those of other iron-based contrast agents such as ferumoxtran-10 and ferucarbotran, developed by companies such as Guerbet and Bayer.

● Mechanism_of_action

Ferumoxytol works by accumulating in areas of interest, such as tumors or inflamed tissues, and altering the magnetic resonance signal, allowing for enhanced contrast and visualization, as demonstrated in studies published in the Journal of Magnetic Resonance Imaging and the American Journal of Roentgenology. The superparamagnetic properties of ferumoxytol enable it to interact with the magnetic field used in MRI, producing a strong T2 relaxation effect, which is similar to the mechanism of action of other superparamagnetic iron oxide particles developed by researchers at University of California, San Francisco (UCSF) and Duke University. Ferumoxytol has been used to image various conditions, including cancer, inflammation, and vascular disease, at institutions such as Memorial Sloan Kettering Cancer Center and Cleveland Clinic. The mechanism of action of ferumoxytol has been studied in detail by researchers at National Cancer Institute (NCI) and the European Institute of Oncology.

● Clinical_uses

Ferumoxytol is used in various clinical applications, including MRI and magnetic resonance angiography (MRA), to visualize blood vessels and diagnose vascular disease, as demonstrated in studies published in the Journal of the American College of Cardiology and the European Heart Journal. It is also used to image tumors and inflammatory lesions, and to monitor treatment response in patients with cancer and other conditions, at institutions such as MD Anderson Cancer Center and University of Chicago. Ferumoxytol has been compared to other contrast agents such as gadolinium-based contrast agents and iodine-based contrast agents in terms of its safety and efficacy profile, as studied by researchers at University of Pennsylvania and University of Michigan. The clinical uses of ferumoxytol have been supported by organizations such as the American College of Radiology (ACR) and the Society of Interventional Radiology (SIR).

● Side_effects

Ferumoxytol is generally well-tolerated, but it can cause adverse reactions such as hypersensitivity reactions, nausea, and headache, as reported in studies published in the Journal of Clinical Pharmacology and the European Journal of Clinical Pharmacology. Rare but serious side effects include anaphylaxis and hypotension, which have been studied in detail by researchers at Mayo Clinic and University of California, San Diego (UCSD). Ferumoxytol has been compared to other iron supplements in terms of its safety profile, and has been found to have a lower risk of adverse reactions such as hypersensitivity reactions and gastrointestinal side effects, as demonstrated in studies published in the Journal of Clinical Gastroenterology and the American Journal of Gastroenterology. The side effects of ferumoxytol have been monitored by organizations such as the FDA and the European Medicines Agency (EMA).

● Pharmacology

Ferumoxytol is administered intravenously and has a half-life of approximately 15 hours, allowing for prolonged imaging and diagnostic capabilities, as demonstrated in studies published in the Journal of Pharmaceutical Sciences and the European Journal of Pharmaceutics and Biopharmaceutics. It is metabolized by the reticuloendothelial system and excreted in the urine and feces, as studied by researchers at University of Washington and University of Texas at Austin. Ferumoxytol has been compared to other iron-based contrast agents in terms of its pharmacokinetic and pharmacodynamic properties, and has been found to have a unique profile that allows for enhanced imaging and diagnostic capabilities, as demonstrated in studies published in the Journal of Magnetic Resonance Imaging and the American Journal of Roentgenology. The pharmacology of ferumoxytol has been studied in detail by researchers at National Institutes of Health (NIH) and the European Organization for Research and Treatment of Cancer (EORTC). Category:Pharmaceuticals